Tier - Palliative Care For Patients With Advanced Heart Failure or Cancer
Launched by ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · Jan 19, 2024
Trial Information
Current as of July 27, 2025
Recruiting
Keywords
ClinConnect Summary
The TIER-PC clinical trial is studying a new approach to providing palliative care for patients with advanced heart failure or certain types of advanced cancer. This program aims to deliver the right kind of support to patients based on their changing needs as their illness progresses. The care is organized into four levels, or "tiers." In the first tier, patients with mild symptoms get help from a community health worker. As symptoms worsen, a social worker and eventually a nurse or doctor join the team to provide more specialized care. This ensures that as patients' needs become more complex, they receive the appropriate support to manage their symptoms and care preferences.
To participate in this trial, individuals must be at least 18 years old, live in Manhattan, and have advanced heart failure or specific types of advanced cancer with certain hospitalizations in the past year. Candidates should be able to communicate in English or Spanish and have the ability to give informed consent. Participants can expect personalized care and support tailored to their needs, as well as regular check-ins to adjust their level of care throughout the trial. This study is currently recruiting participants, and it offers an opportunity to receive comprehensive care during challenging times.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Advanced Heart Failure (HF) with two HF-related hospitalizations within the last 12 months or
- • Advanced lung or non-colorectal gastrointestinal cancer (pancreatic, gastric, hepatobiliary, small bowel, esophageal) with one hospitalization within the last 6 months
- • KPS \> 50% (ECOG 0, 1 or 2)
- • \> 2 outpatient MSHS visits in prior 12 months
- • Manhattan residence
- • Capacity to provide informed consent
- • English or Spanish fluency
- • \> 18 years of age
- Exclusion Criteria:
- • Diagnoses of both cancer and advanced HF
- • Lung cancer with a driver mutation (e.g., EGFR) that confers a favorable prognosis and does not follow typical trajectory
- • Patients with \> 1 visit to Outpatient Supportive Oncology/Cardiology visit
- • Patients with last visit to Outpatient Supportive Oncology/Cardiology \< 3 months ago
- • Previous receipt of a ventricular assist device or previous heart transplantation
- • Receiving hospice care prior to study enrollment or enrolled in another study of a palliative care patient/caregiver intervention
- • Living in a facility (subacute rehab, long-term care facility, hospice facility or residence)
- • Callahan 6-Item Cognitive Screening score ≤3
About Icahn School Of Medicine At Mount Sinai
The Icahn School of Medicine at Mount Sinai is a premier academic institution located in New York City, renowned for its commitment to advancing medical research, education, and patient care. As a leading sponsor of clinical trials, the institution leverages its state-of-the-art facilities and multidisciplinary expertise to drive innovative research initiatives aimed at improving health outcomes. With a focus on translational medicine, the Icahn School of Medicine collaborates with a diverse network of researchers, clinicians, and industry partners to explore novel therapies and interventions across a wide range of medical disciplines. Its rigorous scientific approach and dedication to ethical standards position it as a trusted leader in the clinical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
New York, New York, United States
Patients applied
Trial Officials
Laura P Gelfman, MD, MPH
Principal Investigator
Icahn School of Medicine at Mount Sinai
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported